DE60019774D1 - Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren - Google Patents

Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren

Info

Publication number
DE60019774D1
DE60019774D1 DE60019774T DE60019774T DE60019774D1 DE 60019774 D1 DE60019774 D1 DE 60019774D1 DE 60019774 T DE60019774 T DE 60019774T DE 60019774 T DE60019774 T DE 60019774T DE 60019774 D1 DE60019774 D1 DE 60019774D1
Authority
DE
Germany
Prior art keywords
cationic surface
surface stabilizers
nanoparticles
nanoparticulate compositions
nanoparticle formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019774T
Other languages
English (en)
Other versions
DE60019774T2 (de
Inventor
William Bosch
R Cooper
L Mcgurk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Application granted granted Critical
Publication of DE60019774D1 publication Critical patent/DE60019774D1/de
Publication of DE60019774T2 publication Critical patent/DE60019774T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/12—Powders or granules
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/24—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients to enhance the sticking of the active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/612—By organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/614—By macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
DE60019774T 1999-10-08 2000-10-05 Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren Expired - Lifetime DE60019774T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US414159 1999-10-08
US09/414,159 US6428814B1 (en) 1999-10-08 1999-10-08 Bioadhesive nanoparticulate compositions having cationic surface stabilizers
PCT/US2000/027434 WO2001026635A2 (en) 1999-10-08 2000-10-05 Bioadhesive nanoparticulate compositions having cationic surface stabilizers

Publications (2)

Publication Number Publication Date
DE60019774D1 true DE60019774D1 (de) 2005-06-02
DE60019774T2 DE60019774T2 (de) 2006-03-09

Family

ID=23640205

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019774T Expired - Lifetime DE60019774T2 (de) 1999-10-08 2000-10-05 Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren

Country Status (8)

Country Link
US (3) US6428814B1 (de)
EP (1) EP1217993B1 (de)
JP (2) JP4394324B2 (de)
AT (1) ATE293959T1 (de)
AU (1) AU7993800A (de)
CA (1) CA2386782C (de)
DE (1) DE60019774T2 (de)
WO (1) WO2001026635A2 (de)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810853B1 (de) * 1995-02-24 2004-08-25 Elan Pharma International Limited Nanopartikel-dispersionen enthaltende aerosole
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
WO2000025752A1 (en) 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040057977A1 (en) * 1999-09-22 2004-03-25 Ecolab Inc. Water-based pest bait compositions having water-sensitive insecticides and methods of making and use thereof
DK1913939T3 (en) 2000-06-27 2017-09-18 Vectura Ltd Formulations for use in inhalers
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9089407B2 (en) 2001-04-23 2015-07-28 Massachusetts Institute Of Technology Antibacterial coatings that inhibit biofilm formation on implants
US7151139B2 (en) * 2001-04-23 2006-12-19 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
WO2002085542A1 (en) * 2001-04-23 2002-10-31 Massachusetts Institute Of Technology Antimicrobial polymeric surfaces
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1423175B1 (de) 2001-08-08 2013-10-02 Brown University Research Foundation Verfahren zur mikronisierung von hydrophoben arzneistoffen
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
ES2292848T3 (es) * 2001-10-12 2008-03-16 Elan Pharma International Limited Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada.
IL162183A0 (en) * 2001-12-21 2005-11-20 Celator Technologies Inc Polymer-lipid delivery vehicles and methods for the preparation thereof
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
EP1487419A2 (de) * 2002-03-20 2004-12-22 Elan Pharma International Limited Schnell auflösende dosierformen mit verringerter sprödigkeit
EP1800666A1 (de) * 2002-03-20 2007-06-27 Elan Pharma International Limited Nanopartikelzusammensetzungen von Angiogeneseinhibitoren
ES2380318T3 (es) 2002-04-12 2012-05-10 Alkermes Pharma Ireland Limited Formulaciones nanoparticulares de megestrol
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US8501232B2 (en) * 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
DE60325718D1 (de) * 2002-05-06 2009-02-26 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
US7989503B2 (en) * 2002-05-22 2011-08-02 Nihon Pharmaceutical Co., Ltd. Smooth muscle peristole inhibitor
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
ES2355723T3 (es) * 2002-09-11 2011-03-30 Elan Pharma International Limited Composiciones de agente activo en nanopartículas estabilizadas en gel.
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
AU2002346988A1 (en) * 2002-10-10 2004-05-04 Symrise Gmbh And Co. Kg Perfume hair cosmetic composition
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
US20040173696A1 (en) * 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US20040178135A1 (en) * 2003-03-13 2004-09-16 Beplate Douglas K. Filtering device incorporating nanoparticles
WO2004084859A2 (en) * 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
WO2004087307A1 (fr) * 2003-03-31 2004-10-14 Boris Olegovich Maier Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci.
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US20060121067A1 (en) * 2003-06-30 2006-06-08 Tomonori Hamawaki Menthol-containing preparation
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
CA2534924A1 (en) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
EP1663144A1 (de) * 2003-09-23 2006-06-07 Alcon, Inc. Triamcinolon-acetonid und anecortav-acetat-formulierungen zur injektion
US7837663B2 (en) 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
US7438875B2 (en) 2003-10-16 2008-10-21 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified silica particles
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7879350B2 (en) 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7794737B2 (en) * 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7879360B2 (en) * 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
CA2563609C (en) * 2004-04-22 2012-11-06 Duocort Ab Pharmaceutical compositions for acute glucocorticoid therapy
US20050281775A1 (en) * 2004-06-16 2005-12-22 Carrington Stephen D Mucoadhesive and bioadhesive polymers
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US20060083694A1 (en) 2004-08-07 2006-04-20 Cabot Corporation Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same
WO2006083326A2 (en) * 2004-08-07 2006-08-10 Cabot Corporation Gas dispersion manufacture of nanoparticulates and nanoparticulate-containing products and processing thereof
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
ATE471146T1 (de) 2004-10-21 2010-07-15 Durect Corp Transdermale verabreichungssysteme
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US20080145430A1 (en) * 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
EP1859103B1 (de) * 2005-01-05 2015-04-08 Dow Global Technologies LLC Verstärkte wirkung von fungiziden in papier und pappe
CN101132770A (zh) * 2005-01-06 2008-02-27 伊兰制药国际有限公司 纳米微粒坎地沙坦制剂
CA2597716A1 (en) * 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
EP2767163A1 (de) 2005-02-17 2014-08-20 Abbott Laboratories Transmukosale Verabreichung von Arzneimittelzusammensetzungen zur Behandlung und Vorbeugung von Erkrankungen bei Tieren
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
KR20070118258A (ko) * 2005-03-16 2007-12-14 엘란 파마 인터내셔널 리미티드 나노입자형 류코트리엔 수용체안타고니스트/코르티코스테로이드 제제
MX2007011495A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones de bifosfonato en nanoparticulas.
EA200702049A1 (ru) * 2005-03-23 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции наночастиц кортикостероидов с антигистаминами
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
KR20080007580A (ko) * 2005-04-12 2008-01-22 엘란 파마 인터내셔널 리미티드 사이클로스포린을 함유하는 나노입자형 조절 방출 조성물
MX2007012778A (es) * 2005-04-12 2008-01-11 Elan Pharma Int Ltd Formulaciones de derivados de quinazolina nanoparticuladas.
BRPI0608771A2 (pt) * 2005-05-10 2010-01-26 Elan Pharma Int Ltd formulações de clopidogrel em nanopartìcula
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US20060286239A1 (en) * 2005-05-20 2006-12-21 Philip Morris Usa Inc. Nanoscale materials
CN101262860A (zh) * 2005-06-03 2008-09-10 伊兰制药国际有限公司 纳米微粒对乙酰氨基酚制剂
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
ES2341996T3 (es) * 2005-06-03 2010-06-30 Elan Pharma International Limited Formulaciones de mesilato de imatinib en forma de manoparticulas.
CA2612994A1 (en) 2005-06-08 2006-12-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
MX2007015882A (es) * 2005-06-13 2008-03-04 Elan Pharma Int Ltd Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina.
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
EP1904041A2 (de) * 2005-07-07 2008-04-02 Elan Pharma International Limited Nanopartikuläre clarithromycinformulierung
EP1937217A2 (de) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoteilchenförmige tadalafil-formulierungen
EP1933814A2 (de) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoteilchenförmige aripiprazol-formulierungen
US20080249136A1 (en) * 2005-10-25 2008-10-09 Ioana Annis Antimicrobial Composition and Method
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP5334588B2 (ja) * 2005-11-28 2013-11-06 マリナス ファーマシューティカルズ ガナキソロン製剤、およびその作製方法、およびその使用
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US7977103B2 (en) 2006-04-20 2011-07-12 Kimberly-Clark Worldwide, Inc. Method for detecting the onset of ovulation
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
JP2009538927A (ja) * 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド ナノ粒子状のポサコナゾール製剤
WO2007147014A2 (en) * 2006-06-13 2007-12-21 Fmc Biopolymer As Method and systems for using biopolymer-based beads and hydrogels
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
CA2653384C (en) 2006-06-30 2017-03-14 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
EP2084234A2 (de) * 2006-11-08 2009-08-05 Massachusetts Institute of Technology Polymere beschichtungen zur deaktivierung von viren und bakterien
KR20090091321A (ko) 2006-11-28 2009-08-27 마리누스 파마슈티컬스 나노입자 제형, 이의 제조방법 및 이의 용도
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
EP2134830A2 (de) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oszillations-zellkultur-bioreaktor
EP2139470A4 (de) * 2007-03-23 2010-07-28 Elan Pharma Int Ltd Mit gammastrahlen sterilisierte nanoteilchenförmige docetaxel-zusammensetzungen und herstellungsverfahren dafür
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US20080268140A1 (en) 2007-04-26 2008-10-30 Csd, Inc. Temporary removable solvent based protective coating
US8221574B2 (en) 2007-04-26 2012-07-17 Csd, Llc Top coating for indoor and outdoor temporary removable graphics and system and method for making, applying and removing such graphics
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US20080279784A1 (en) * 2007-05-07 2008-11-13 Questcor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP2162120B1 (de) * 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
JP5628031B2 (ja) 2007-07-25 2014-11-19 スリーエム イノベイティブ プロパティズ カンパニー 治療用歯科用組成物及び関連する方法
JP5453260B2 (ja) * 2007-07-25 2014-03-26 スリーエム イノベイティブ プロパティズ カンパニー 被膜形成歯科用組成物及び関連する方法
ES2627292T3 (es) 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
GB2458403B (en) * 2007-11-13 2010-01-13 Meritage Pharma Inc Stabilised corticosteroid compositions
CN101969956B (zh) * 2007-11-13 2014-03-05 梅里蒂奇制药公司 皮质类固醇组合物
US20090148491A1 (en) * 2007-12-05 2009-06-11 Abbott Cardiovascular Systems Inc. Dual-Targeted Drug Carriers
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
CA2715422A1 (en) * 2008-03-21 2009-09-24 Elan Pharma International Limited Compositions for site-specific delivery of imatinib and methods of use
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US8791064B2 (en) * 2008-04-24 2014-07-29 Technion Research And Development Foundation Ltd. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds
AU2009256194A1 (en) 2008-06-06 2009-12-10 Avery Dennison Corporation Temporary outdoor graphic film
TWI580441B (zh) * 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
KR20140077945A (ko) 2009-04-24 2014-06-24 아이슈티카 피티와이 리미티드 신규 인도메타신 제제
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
US8709455B2 (en) 2009-06-15 2014-04-29 Chemyunion Quimica Ltda. Sericin cationic nanoparticles for application in products for hair and dyed hair
CN102497857A (zh) 2009-06-19 2012-06-13 纳米模型匈牙利有限公司 纳米结构的西地那非碱、其药学可接受的盐和共结晶、它们的组合物、其制备方法和包含它们的药物组合物
UA109772C2 (uk) * 2009-07-02 2015-10-12 Агент для підвищення гідрофільності ґрунту і способи його застосування
WO2011095970A1 (en) * 2010-02-07 2011-08-11 J.P.M.E.D. Ltd. Hair follicle targeting compositions
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
GB201011905D0 (en) 2010-07-15 2010-09-01 Unilever Plc Benefit delivery particle,process for preparing said particle,compositions comprising said particles and a method for treating substrates
US9005664B2 (en) * 2010-10-17 2015-04-14 Technion Research And Development Foundation Ltd. Denatured lactoglobulin and polyphenol coassemblies
EP2701668A1 (de) 2011-04-29 2014-03-05 Massachusetts Institute of Technology Schichtbearbeitung für pharmazeutika
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
US10058500B2 (en) 2011-11-30 2018-08-28 Fundació Institut De Ciències Fotòniques Method for enhanced photoepilation based on metallic nano-complexes
US9408419B2 (en) 2012-03-23 2016-08-09 Victoria's Secret Store Brand Management, Inc. Moisturizing fabric material, use thereof in moisturizing bras, and method of manufacture
US20130295143A1 (en) * 2012-05-02 2013-11-07 Massachusetts Institute Of Technology Electroprocessing of active pharmaceutical ingredients
US9334200B2 (en) 2013-01-28 2016-05-10 Bfp Management, Llc Fertilizer composition and method for suspending fertilizer in an aqueous solution
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
JP2015209380A (ja) 2014-04-24 2015-11-24 ロレアル 化粧用組成物
US10213960B2 (en) 2014-05-20 2019-02-26 Massachusetts Institute Of Technology Plasticity induced bonding
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
US10987434B2 (en) 2015-10-21 2021-04-27 The Regents Of The University Of Michigan Detection and treatment of caries and microcavities with nanoparticles
EP3481387A4 (de) 2016-08-11 2020-04-08 Ovid Therapeutics Inc Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
JP2020528408A (ja) * 2017-07-19 2020-09-24 デンツプライ シロナ インコーポレイテッド 水溶性ヒドロゲル系歯科用組成物ならびにその調製および使用方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
WO2021087359A1 (en) 2019-11-01 2021-05-06 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
KR20220126287A (ko) 2019-11-14 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 멀티모달 조성물 및 치료 방법
CA3158280A1 (en) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone for use in treating tuberous sclerosis complex
JP2024505429A (ja) 2021-01-15 2024-02-06 アクエスティブ セラピューティクス インコーポレイテッド プロドラッグ組成物及び治療の方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4757059A (en) * 1984-08-14 1988-07-12 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
US4663364A (en) 1984-09-05 1987-05-05 Kao Corporation Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS62185013A (ja) 1986-02-08 1987-08-13 Green Cross Corp:The 易吸収性医薬組成物
DE3620685A1 (de) * 1986-06-20 1987-12-23 Henkel Kgaa Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut
EP0262560A3 (de) 1986-09-29 1989-07-05 Ishihara Sangyo Kaisha, Ltd. Benzoyl-Harnstoff-Verbindungen
US4983605A (en) 1986-10-23 1991-01-08 Ishihara Sangyo Kaisha Ltd. Pharmaceutical composition
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
EP0315589B1 (de) 1987-11-03 1993-09-08 ILFORD Limited Vorrichtung zur Herstellung geänderter Abdrucke
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
JP2661709B2 (ja) 1988-07-08 1997-10-08 ダウ・ケミカル日本株式会社 高活性な農薬水和剤の製法
ES2052016T3 (es) * 1988-09-29 1994-07-01 Shiseido Co Ltd Composicion emulsionada.
JPH02196719A (ja) 1989-01-24 1990-08-03 Green Cross Corp:The 粉末状医薬組成物
US5750134A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
AU7077091A (en) 1990-01-11 1991-08-05 E.I. Du Pont De Nemours And Company Herbicidal pyrimidines and triazines
US5156767A (en) * 1990-01-16 1992-10-20 Conoco Inc. Emulsion breaking using alkylphenol-polyethylene oxide-acrylate polymer coated coalescer material
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
CA2112905A1 (en) 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
HU9203730D0 (en) 1991-12-06 1993-03-29 Sandoz Ag Substituted phthalides and heterocyclic ones
JPH07112936A (ja) 1992-04-27 1995-05-02 Philippe Perovich 治療用成分、とくにアスピリンに基づく成分の製剤方法
WO1994011482A1 (en) 1992-11-16 1994-05-26 The Procter & Gamble Company Fabric softening compositions with dye transfer inhibitors for improved fabric appearance
ES2077547T3 (es) * 1992-11-17 2000-06-16 Yoshitomi Pharmaceutical Microesfera de liberacion sostenida que contiene un antipsicotico y procedimiento de produccion.
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE4324396A1 (de) 1993-07-21 1995-01-26 Henkel Kgaa Reinigungsmittel mit hohem Benetzungsvermögen
US6177104B1 (en) * 1994-01-27 2001-01-23 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving dosage form
US5912219A (en) 1994-02-03 1999-06-15 The Procter & Gamble Company Acidic cleaning compositions
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
BE1008307A3 (fr) * 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5707981A (en) 1994-07-28 1998-01-13 Psorial, L.L.C. Synergistic pharmaceutical compositions
CZ285638B6 (cs) 1994-10-07 1999-10-13 Eka Chemicals Ab Částice obsahující peroxysloučeninu a prostředek, který je obsahuje
US5935271A (en) 1994-10-13 1999-08-10 Procter & Gamble Company Laundry detergent compositions containing lipolytic enzyme and amines
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5853756A (en) * 1995-01-11 1998-12-29 J. B. Chemicals & Pharmaceuticals Limited Controlled release formulations of Ranitidine
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5632996A (en) * 1995-04-14 1997-05-27 Imaginative Research Associates, Inc. Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
AU6742196A (en) 1995-08-15 1997-03-12 Novartis Ag Pesticidal indazole derivatives
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5932535A (en) 1995-12-21 1999-08-03 Henkel Kommanditgesellschaft Auf Aktien Process for the production of light-colored, low-viscosity surfactant concentrates
IL123636A (en) * 1995-12-27 2001-04-30 Janssen Pharmaceutica Nv Bioadhesive compounds, tablets containing them and a method of preparing the tablets
JP4107693B2 (ja) 1996-02-09 2008-06-25 保土谷化学工業株式会社 固体粒子水性懸濁液の製造方法
KR970061942A (ko) * 1996-02-09 1997-09-12 무또 미노루 복합 입자 수성 현탁액 및 이의 제조 방법
US5932202A (en) 1996-03-27 1999-08-03 The Procter & Gamble Company Conditioning shampoo composition
US5935561A (en) 1996-03-27 1999-08-10 Procter & Gamble Company Conditioning shampoo compositions containing select hair conditioning agents
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE69724986T2 (de) 1996-06-07 2004-07-15 Hercules Inc., Wilmington Zahnpasten enthaltend carboxymethylcellulose fluidisierte suspensionen
EP0818450B1 (de) * 1996-07-08 2003-01-15 Ciba SC Holding AG Triazinderivate als UV-Filter in Sonnenschutzmitteln
KR100360522B1 (ko) * 1996-07-25 2002-11-13 니키 유니바사루 가부시키가이샤 공기 정화 필터
RO120603B1 (ro) 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5932404A (en) 1996-12-18 1999-08-03 Eastman Kodak Company Silver halide photographic material containing a polymer with a photographically useful group which is rendered non-diffusible by cross-linking
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
GB9703552D0 (en) * 1997-02-20 1997-04-09 Dow Corning Polymerisation of cyclosiloxanes in the presence of fillers
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
JP3950175B2 (ja) * 1997-05-30 2007-07-25 オスモティカ・コーポレイション 多層浸透デバイス
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US5929024A (en) 1997-11-20 1999-07-27 Colgate Palmolive Company Cleaning compositions
US5938017A (en) * 1998-05-04 1999-08-17 Wik; Dennis O. Article for assisting persons to quit smoking and method for same
US6177103B1 (en) * 1998-06-19 2001-01-23 Rtp Pharma, Inc. Processes to generate submicron particles of water-insoluble compounds
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US5935921A (en) 1999-01-26 1999-08-10 Colgate-Palmolive Co. Liquid descaling composition
US5935272A (en) 1999-02-02 1999-08-10 Milliken & Company Compositions comprising aryloxypolyoxyalkylene naphthalimide derivative colorants
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
ES2367352T3 (es) 1999-04-28 2011-11-02 Genetics Institute, Llc Tratamiento de la fibrosis meidante el antagonismo de la il-3 y de las cadenas del receptor del il-3.
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR100364496B1 (ko) * 2000-07-14 2002-12-12 에쓰대시오일 주식회사 마이크로파를 이용한 폴리카보네이트 수지의 제조방법
DE60227802D1 (de) 2001-06-05 2008-09-04 Elan Pharma Int Ltd Mahlvorrichtung und verfahren zu deren betrieb
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP4502318B2 (ja) 2004-06-02 2010-07-14 河村電器産業株式会社 漏電遮断器

Also Published As

Publication number Publication date
ATE293959T1 (de) 2005-05-15
EP1217993B1 (de) 2005-04-27
CA2386782A1 (en) 2001-04-19
US7288267B2 (en) 2007-10-30
WO2001026635A2 (en) 2001-04-19
CA2386782C (en) 2009-12-15
AU7993800A (en) 2001-04-23
JP2003511406A (ja) 2003-03-25
JP4394324B2 (ja) 2010-01-06
US20020068092A1 (en) 2002-06-06
DE60019774T2 (de) 2006-03-09
WO2001026635A3 (en) 2001-09-13
US6428814B1 (en) 2002-08-06
US20080003295A1 (en) 2008-01-03
US7850995B2 (en) 2010-12-14
JP2010018604A (ja) 2010-01-28
US20030108611A1 (en) 2003-06-12
EP1217993A2 (de) 2002-07-03

Similar Documents

Publication Publication Date Title
ATE293959T1 (de) Bioadhäsive nanopartikelformulierungen mit kationischen oberflächenstabilisatoren
TW200946022A (en) Moisturizing hand sanitizer
FR2843125B1 (fr) Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
ES2786084T3 (es) Composiciones antimicrobianas mejoradas
CA2424003A1 (en) Anti-microbial topical composition comprising alcohol and chlorhexidine salt
JP6449484B2 (ja) パウダー状害虫忌避組成物、及びその製造方法
PL1715739T3 (pl) Formułowanie synergistycznej kompozycji owadobójczej jako kompleksu z cyklodekstryną
CN105431154A (zh) 抗菌成分
KR102387616B1 (ko) 해충 기피 조성물, 및 해충 기피 방법
US9844596B2 (en) Compositions for depositing agents using highly volatile silicone solvents
BR0108994A (pt) Composições pesticidas e seu uso como agentes protetores
ES2224386T3 (es) Composicion para pulverizador contra hormigas que contiene d-limoneno y procedimientos para su preparacion y uso de la misma.
CN104684532B (zh) 聚合物颗粒的水分散体，包含该水分散体的成膜组合物及其用途
JP4278932B2 (ja) ゲル素材溶液
AR023483A1 (es) ENANTIOMERO (-) DE LA 2-[-2-(1-CLORO-CICLOPROPIL)-3-(2-CLOROFENIL)-2-HIDROXIPROPIL]-2HIDROXIPROPIL ] -2,4-DIHIDRO-[1,2,4]-TRIAZOL-3-TIONA, PROCEDIMIENTO PARA SU PREPARACIoN, COMPOSICION MICROBICIDA, USO DE DICHO ENANTIOMERO PARA LA LUCHA CONTRA MICROORGANISMOS INDESEADOS EN LA PROTECCIoN DE CULTIVOS
ES2922644B2 (es) Composicion higienizante y uso de la misma
KR20050077237A (ko) 살균소독용 샴푸(shampoo) 조성물
JP2016147869A (ja) メチルメルカプタン発生抑制用口腔用組成物
CZ2017210A3 (cs) Prostředek na hubení vší
KR101346797B1 (ko) Ｐｃｍｘ를 이용한 세정제 조성물 및 이의 제조방법
US20210402017A1 (en) Method for inactivating a virus on a surface
JP5228203B2 (ja) 有害生物防除剤及びその使用方法
JP2018058887A (ja) メチルメルカプタン発生抑制用口腔用組成物
CZ31201U1 (cs) Prostředek na hubení vší
TH71513A (th) สารผสมฆ่ารา

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN